Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

26 10.4

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

23.49

Maximum

26.63

Fő mutatók

By Trading Economics

Bevétel

-607K

-51M

Értékesítés

-28M

100M

Egy részvényre jutó nyereség

-0.46

Profit margin

-51.215

Munkavállalók

1,784

EBITDA

4.1M

-44M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+38.52% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-331M

2.1B

Előző nyitás

15.6

Előző zárás

26

Hangulat hírek alapján

By Acuity

50%

50%

128 / 340 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 10. 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

2026. aug. 10. 23:52 UTC

Event
News
Social Media

Plug Power shares are higher in after-market trading following strong second-quarter results that exceeded analyst expectations and an improved revenue growth outlook.

2026. aug. 10. 23:51 UTC

News

First Horizon Corp shares rise in after-market hours following James Petrillo's appointment as Vice President, De Novo New Build Leader to enhance banking centers.

2026. aug. 10. 23:51 UTC

News
Social Media

Riot Platforms reported Q2 revenue of $174.2 million, exceeding expectations. Shares rose sharply in after-hours trading following a major data center lease announcement.

2026. aug. 10. 23:51 UTC

News
Social Media

FutureFuel Corp reported second-quarter revenues of $78.7 million, a 120.6% increase year-over-year. Shares are trading higher in after-market hours following the results.

2026. aug. 10. 23:51 UTC

Event
News
Social Media

Upwork Inc. shares fell sharply in after-market hours following disappointing second-quarter results and lowered full-year revenue guidance of $730 million to $750 million.

2026. aug. 10. 23:46 UTC

News

Fortuna Silver Mines acquires the Bambadji Project for $200 million, boosting growth potential in West Africa. Shares are higher in after-market trading.

2026. aug. 10. 23:42 UTC

News

AT&T Inc. filed a $1.1 billion term sheet for floating rate notes due in 2028, contributing to lower shares in after-market trading.

2026. aug. 10. 23:41 UTC

News

Kyndryl Holdings plans to acquire Healthcare IT Leaders to enhance its healthcare capabilities. Shares are trading higher in after-market hours following the announcement.

2026. aug. 10. 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

2026. aug. 10. 23:41 UTC

News

Enphase Energy shares are lower in after-market trading following governance enhancements announced by the board after its 2026 Annual Meeting vote.

2026. aug. 10. 23:41 UTC

News

Toast Inc. shares are trading lower in after-market hours following Elena Gomez's sale of 17,076 shares, reducing her ownership by 9%.

2026. aug. 10. 23:41 UTC

News

Harrow Inc shares declined in after-market hours following a second-quarter EPS miss of -$0.46, despite revenue of $70.66 million exceeding expectations.

2026. aug. 10. 23:41 UTC

News

Hf Foods Group Inc reported strong Q2 results, with revenue of $323.8 million and GAAP net income of $2.6 million, driving shares higher in after-market hours.

2026. aug. 10. 23:41 UTC

News

Curtiss-Wright Corp raised its share repurchase program to $160 million, boosting investor sentiment as shares gained during after-market hours.

2026. aug. 10. 23:41 UTC

News
Social Media

Hims & Hers Health reported a net loss of $86.3 million in Q2, contributing to a decline in share price during after-market trading.

2026. aug. 10. 23:41 UTC

News

Rapid7 shares rise in after-hours trading following second-quarter results that exceeded expectations and positive third-quarter guidance.

2026. aug. 10. 23:41 UTC

Event
News

Alcon AG reported second-quarter adjusted EPS of $0.84, surpassing estimates. The company raised its fiscal 2026 EPS guidance, boosting shares in after-market hours.

2026. aug. 10. 23:41 UTC

News
Social Media

Entravision Communications shares fell sharply after reporting mixed Q2 results, with earnings of $0.19 and revenues of $227.9 million amid declining broadcast advertising revenue.

2026. aug. 10. 23:41 UTC

News

Celsius Holdings Inc. shares are lower in after-market trading following significant leadership changes, including the departure of President Eric Hanson.

2026. aug. 10. 23:36 UTC

News

Purple Innovation shares fell after the company reported Q2 2026 earnings of -$0.74, missing estimates, and reduced full-year revenue guidance to $420 million to $440 million.

2026. aug. 10. 23:36 UTC

Correlated Moves
News

Pomerantz LLP has filed a class action lawsuit against Zillow Group Inc, contributing to a decline in shares during after-market trading.

2026. aug. 10. 23:36 UTC

News

Valero Energy shares are higher in after-market trading, reflecting a five-year average annual return of 36.59%, turning a $100 investment into $468.33.

2026. aug. 10. 23:36 UTC

News

Phillips Edison & Co Inc shares are lower in after-market hours following a $400 million stock sale announcement, raising concerns over potential dilution.

2026. aug. 10. 23:31 UTC

News

Tactile Systems Technology shares fell in after-market hours following a revenue guidance cut, despite a rise in net income and adjusted EBITDA surpassing expectations.

2026. aug. 10. 23:31 UTC

News

L3Harris Technologies completed a successful hot-fire test for the Next Generation Interceptor program, boosting shares in after-market trading.

2026. aug. 10. 23:31 UTC

News

Definitive Healthcare reported Q2 adjusted EPS of $0.05, exceeding estimates. The stock rose sharply during after-market hours amid positive guidance and CEO comments.

2026. aug. 10. 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

2026. aug. 10. 23:26 UTC

News

RadNet Inc reported record Q2 revenue and adjusted EBITDA. Shares are trading higher in after-market hours, reflecting positive investor sentiment following the earnings report.

2026. aug. 10. 23:21 UTC

News
Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

38.52% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 32.65 USD  38.52%

Magas 45 USD

Alacsony 21.6 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

3

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

128 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat